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ABSTRACT The dose- and time-dependent changes of in vivo radioligand binding to
the neuronal membrane dopamine transporter (DAT) and vesicular monoamine trans-
porter type 2 (VMAT2) were examined in mouse brain after MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) administrations. Regional brain distribution studies were
done in male C57BL/6 mice using simultaneous injections of d-threo-[3H]methylpheni-
date (DAT) and (1)-a-[11C]dihydrotetrabenazine (VMAT2). Single (55 mg/kg i.p.) or
multiple (4 3 10 mg/kg i.p., 1-hour intervals) administration of MPTP caused significant
reductions in [3H]methylphenidate and [11C]dihydrotetrabenazine specific striatal bind-
ing, measured 14 days later. The single high dose of MPTP produced greater losses of
[11C]dihydrotetrabenazine binding than did the multiple MPTP dosing regimen. Using
the single high dose of MPTP, changes of in vivo binding of the two radioligands were
determined at 1, 3, and 14 days after neurotoxin injection. At 1 day, there are large losses
of [3H]methylphenidate binding (DAT) but no changes in [11C]dihydrotetrabenazine
binding to the VMAT2 site in the striatum. At 3 and 14 days, there were .50% losses of
binding of both bot radioligands, but significantly (P , 0.001) greater losses of VMAT2
binding of [11C]dihydrotetrabenazine. These studies indicate that the losses of the
neuronal membrane and vesicular transporters are not always equal, and do not occur in
the same time frame, after administration of the neurotoxin MPTP. Synapse 35:250–
255, 2000. r 2000 Wiley-Liss, Inc.
INTRODUCTION
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine) intoxication of mice has been repeatedly used as a
model of the dopaminergic terminal degeneration in the
brains of humans suffering from Parkinson’s disease.
Although MPTP lesioning does not completely mimic
the time course and biochemical changes seen in a long
chronic condition such as Parkinson’s disease, the
mouse MPTP model has been an invaluable tool in
studies of the mechanisms of and potential treatments
for dopaminergic nerve terminal losses (Gerlach and
Riederer, 1996).
The most commonly used indicator of dopaminergic
terminal toxicity has been the loss of dopamine in the
striatum; other biochemical measures of dopaminergic
neurons, including aromatic amino acid decarboxylase
(AADC), tyrosine hydroxylase (TH), and neuronal mem-
brane dopamine transporters (DAT) have also been
widely utilized (Gerlach and Riederer, 1996). Recently,
the use of radioligands for the vesicular monoamine
transporter type 2 (VMAT2) as in vitro (Scherman et
al., 1989; Vander Borght et al., 1995; Wilson et al.,
1996) and in vivo (Frey et al., 1996; Kilbourn, 1997)
measures of dopaminergic terminals has been pro-
posed, based on the observation that the majority
(about 95%) of monoaminergic terminals in the stria-
tum are dopaminergic. In MPTP-treated mice, the
vesicular monoamine transporter binding site is lost
(Kilbourn et al., 1998), just as are the other specific
biochemical measures of presynaptic dopaminergic ter-
minals. Recent studies of degeneration following MPTP
administrations have clearly shown that this process,
although rapidly initiated, may reach completion only
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after several days (Jackson-Lewis et al., 1995). Further-
more, losses of specific dopaminergic markers are not
always equal and may not occur in the same time
frame.
The potential differences in MPTP-induced losses of
DAT and VMAT2 binding sites have not been previ-
ously examined. This has relevance to the choice of
radioligand for in vivo imaging studies of Parkinson’s
and other degenerative diseases; we have recently
hypothesized that the vesicular transporter may be a
better marker of neuronal losses (Kilbourn et al., 1998)
as the concentrations of that transporter may be less
likely to be regulated than the DAT, which can clearly
be altered by drug treatments (Vander Borght et al.,
1995; Wilson et al., 1996) and is hypothesized to
undergo compensatory regulation in disease (Zigmond,
1997). In the experiments reported here, the use of
MPTP-treated mice provides a model to examine
whether the neuronal membrane dopamine and vesicu-
lar monoamine transporters, both specific presynaptic
markers of dopaminergic terminals in the striatum, are
lost at the same rate and extent during MPTP-induced
degeneration.
MATERIALS AND METHODS
d-threo- [3H]Methylphenidate (specific activity 83
Ci/mmol) was prepared (Amersham, Arlington Heights,
IL) by a two-step synthesis involving [3H]methylation
and subsequent deprotection of the ritalinic acid precur-
sor, following the procedure used for synthesis of
[11C]methylphenidate (Ding et al., 1994). (1)-a-[11C]Di-
hydrotetrabenazine (specific activity .500 Ci/mmol)
was prepared by [11C]methylation of the 9-O-desmethyl
precursor, as previously described (Jewett et al., 1997).
MPTP was obtained from Aldrich Chemical Co.
Studies were done in male C57BL/6 mice (20–25 g,
7–8 weeks old; Charles Rivers, Portage, MI). Animals
were divided into five groups. Groups A (N 5 7), B (N 5
8), and C (N 5 7) received a single 55 mg/kg i.p. dose of
MPTP. Group D (N 5 8) received four injections of 10
mg/kg MPTP i.p. at 1-hour intervals. Group E (N 5 8)
received a single injection of 0.9% saline (control ani-
mals). All injections were done at room temperature
(23°C) under light diethyl ether anesthesia; for the
multiple MPTP administrations animals were allowed
to recover between injections. No attempts were made
to control for hypothermia in any animals.
Regional brain distribution studies were done at the
following times after the last or single MPTP adminis-
tration: Group A at 24 hours, Group B at 3 days, and
Groups C–E at 14 days. Animals were anesthetized
(diethyl ether) and a mixture of d-threo- [3H]methylphe-
nidate (5–6 µC) and (1)-a-[11C]dihydrotetrabenazine
(175–275 µC) injected via the tail vein. Animals were
allowed to awaken, then anesthetized at 20 minutes
and killed by decapitation. The brains were quickly
removed and dissected into the following regions of
interest: striatum, cortex (whole), hippocampus, hypo-
thalamic region, and cerebellum. Tissue samples were
rapidly weighed and then counted for carbon-11 in an
automatic g-counter. Tissue solubolizer was added, and
after digestion the scintillation fluid was added and the
sample counted again for tritium (automatic b-counter).
For both isotopes, data were calculated as percent
injected dose per gram of tissue (%ID/g). Specific bind-
ing in regions of the brain was calculated as [(%injected
dose/g region)/(% injected dose/g cerebellum)]-1.
Comparisons between groups were initially done
using unpaired Student’s t-tests. To evaluate the differ-
ence between radioligands within a set of animals, a
2-factor repeated measures ANOVA was utilized. In all
cases, a P , 0.05 was considered significant.
RESULTS
Radioligand distributions in control mice
The regional brain radioactivity concentrations and
specific binding (defined as region/cerebellum—1) for
[3H]methylphenidate and [11C]dihydrotetrabenazine are
shown in Table I. For both radiotracers, the highest
concentrations of radioactivity are seen in the striatum,
and the actual concentrations (%ID/g) are quite similar.
MPTP: single vs. multiple doses
The effects of single (55 mg/kg) and multiple (4 3 10
mg/kg, 1-hour interval) injections of MPTP on specific
radioligand binding in the striatum, determined 14
days after neurotoxin injection, are shown in Table II.
Specific binding of [3H]methylphenidate in striatum
was reduced by 51% (single dose) and 32% (multiple
dose), with a non-significant trend (P 5 0.1) towards a
greater loss of binding after the single high dose
treatment. Specific binding of [11C]dihydrotetrabena-
zine in the striatum was reduced 69 and 49% after
single and repeated doses of MPTP, respectively, and
the greater loss after the single MPTP dose was signifi-
cant (P , 0.05). For both dose regimens, there was a
TABLE I. Regional radioactivity concentrations (%ID/g, percent
injected dose/g tissue) and specific binding ([%ID/g region/%ID/
g cerebellum)]-1) for [3H]methylphenidate and
[11C]dihydrotetrabenazine in control C57BL/6 mouse brain*
Region %ID/g Specific binding
[3H]Methylphenidate
Striatum 5.38 6 0.93 0.90 6 0.21
Cortex 4.05 6 0.33 0.44 6 0.10
Hippocampus 3.70 6 0.44 0.31 6 0.09
Hypothalamus 2.54 6 0.86 —
Cerebellum 2.83 6 0.33 —
[11C]Dihydrotetrabenazine
Striatum 4.98 6 1.02 1.47 6 0.29
Cortex 1.88 6 0.27 —
Hippocampus 1.64 6 0.28 —
Hypothalamus 2.49 6 0.66 0.257 6 0.21
Cerebellum 1.97 6 0.23 —
*Data are shown as mean 6 SD (N 5 8).
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greater loss of in vivo specific binding of [11C]dihydrotet-
rabenazine as compared to [3H]methylphenidate (P ,
0.0001).
Time course of changes after MPTP
In Figure 1 are shown the losses of in vivo specific
binding of [11C]dihydrotetrabenazine and [3H]methyl-
phenidate in the mouse striatum at 1, 3, and 14 days
after a single 55 mg/kg dose of MPTP. At one day,
greater than 50% of the in vivo [3H]methylphenidate
binding to the DAT has been lost (controls, 0.90 6 0.21;
MPTP-treated, 0.39 6 0.09, P , 0.01), with a slight but
non-significant improvement in specific binding at 14
days (0.47 6 0.19). In contrast, at one day there is no
significant change of the in vivo binding of [11C]dihydro-
tetrabenazine to the VMAT2. By three days, and persist-
ing to 14 days, the [11C]dihydrotetrabenazine binding
has decreased significantly (69% loss: controls, 1.48 6
0.29; MPTP-treated, 0.46 6 0.20, P , 0.01), and to a
greater extent than the loss of [3H]methylphenidate
binding (P , 0.001). Specific binding of [11C]dihydrotet-
rabenazine did not show any trend towards improve-
ment at 14 days.
DISCUSSION
In this experiment, the dose- and time-dependent
changes of in vivo radioligand binding to the dopamine
neuronal transporter (DAT) and vesicular monoamine
transporter (VMAT2) in the mouse brain were deter-
mined following treatments with one or multiple doses
of MPTP. These studies have demonstrated that losses
of in vivo radioligand binding to the two transporters
does not occur at the same rate or to the same extent.
DAT and VMAT2 radioligand binding in vivo:
control animals
The regional distributions for both [3H]methylpheni-
date and [11C]dihydrotetrabenazine are consistent with
in vitro Bmax values for in vitro radioligand binding to
the respective transporter (DAT and VMAT2) and are
very similar to the in vivo regional distributions previ-
ously reported using these radioligands in the rodent
brain (Gatley et al., 1995; Kilbourn, 1997; Kilbourn et
al., 1995, 1998). The regional distributions of the two
ligands do not correlate with each other (r2 5 0.59 for
all regions, r2 5 0.2 without striatum). For [11C]dihydro-
tetrabenazine, there is intermediate specific binding to
monoaminergic terminals (dopaminergic, serotonergic,
and adrenergic) in the hypothalamus, which can be
competed for by cold VMAT2 antagonists (Kilbourn and
Sherman, 1997), and insignificant specific binding in
the cortex. For [3H]methylphenidate, low but discern-
TABLE II. Losses of [3H]methylphenidate and [11C]dihydrotetrabenazine binding in vivo in regions of
mouse brain after single and multiple doses of MPTP†
Region
MPTP dose
None (N 5 8) 1 3 55 mg/kg (N 5 7) 4 3 10 mg/kg (N 5 8)
[3H]Methylphenidate
Striatum 0.90 6 0.22 0.47 6 0.19 (248%)* 0.62 6 0.24 (232%)*
Cortex 0.44 6 0.10 0.43 6 0.05 0.47 6 0.10
Hypothalamus nd nd nd
Hippocampus 0.31 6 0.10 0.36 6 0.09 0.36 6 0.01
[11C]Dihydrotetrabenazine
Striatum 1.47 6 0.29 0.47 6 0.25 (268%)*,** 0.76 6 0.25 (248%)*,**
Cortex nd nd nd
Hypothalamus 0.13 6 0.22 0.13 6 0.16 0.43 6 0.17
Hippocampus nd nd nd
†Values shown are mean 6 SD (N 5 7) for specific binding, defined as ([%ID/g region/%ID/g cerebellum]-1). nd 5 no
detectable specific binding.
*P , 0.05 vs. controls.
**P , 0.001 vs [3H]methylphenidate.
Fig. 1. Time course of losses of in vivo binding of [11C]dihydrotetra-
benazine (DTBZ) and [3H]methylphenidate (MePhen) to striatum of
mice injected with 55 mg/kg i.[p. MPTP. Data shown are percent of
mean control group values. Differences between the radioligands were
statistically significant (P , 0.001) at all time points after MPTP
administration.
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able levels of residual radioactivity are observed in
cortex and hippocampus and very low levels in the
hypothalamus; in the rat, however, none of the
[3H]methylphenidate uptake in these regions can be
blocked by administration of cold methylphenidate
(Kilbourn and Sherman, unpublished results), and
thus likely do not represent significant specific binding.
Single vs. multiple doses of MPTP
A single high dose of MPTP (55 mg/kg) was appar-
ently more neurotoxic than multiple low doses (4 3 10
mg/kg, 1-hour intervals), as demonstrated by greater
losses of both [11C]dihydrotetrabenazine and [3H]meth-
ylphenidate binding (Table II). Although many investi-
gators have utilized multiple injections of MPTP to
create dopaminergic lesions, there is ample literature
showing that a single high dose of MPTP is neurotoxic
and produces significant losses of striatal dopamine
concentrations and dopamine uptake (Freyaldenhoven
et al., 1995, 1997; Hoskins and Davies, 1989; Jossan et
al., 1989; Pileblad and Carlsson, 1988; Pileblad et al.,
1985; Vaglini et al., 1996). We have previously shown
that the multiple injection protocol (4 3 10 mg/kg)
reduced in vivo radioligand binding to the dopamine
transporter (using [18F]GBR 13119 as radioligand: Kil-
bourn et al., 1991) as well as the VMAT2 (using
[3H]dihydrotetrabenazine as radioligand; Kilbourn et
al., 1998) in mouse striatum. It was not clear, however,
if the simpler single injection protocol would produce
equivalent decrements of in vivo radioligand binding.
Surprisingly, and quite unexpectedly, the single 55
mg/kg MPTP dose produced clearly larger losses of
VMAT2 radioligand binding, and a trend towards
greater loss of DAT radioligand binding.
Comparisons of results previously obtained from
MPTP administrations, including both single-dose and
multiple dose regimens, are quite difficult as there have
been no consistent protocols regarding neurotoxin doses,
intervals between MPTP administrations, intervals
from administration to analysis, mouse strains and
sources, and biochemical measures (dopamine levels,
dopamine transporter, vesicular monoamine trans-
porter, TH enzyme activity). To minimize such difficul-
ties in comparing studies, we utilized here a single
group of C57BL/6 mice of identical sex and age, from a
single supplier, with neurotoxin injections (single vs.
multi-dose protocols) done on consecutive days. This
should have minimized any potential differences be-
tween the groups, and the greater losses of [3H]dihydro-
tetrabenazine binding to the VMAT2 site can be attrib-
uted to the MPTP dose regimen alone.
Time course of losses of radioligand binding
There was a difference in both the rate and extent of
loss of in vivo radioligand binding to the DAT and the
VMAT2 following the single MPTP dose. At 24 hours
the in vivo binding of [3H]methylphenidate to the DAT
had decreased by 50%, but [11C]dihydrotetrabenazine
binding to the VMAT2 remained unchanged. At 3 days,
and persisting at 14 days, both radioligands showed
losses of in vivo binding, with a greater loss of [11C]dihy-
drotetrabenazine binding to the VMAT2.
Differential losses of dopaminergic markers after
MPTP treatment have been reported numerous times,
but this is the first study demonstrating a differential
loss of the DAT and VMAT2. For applications of such
radioligands as markers of dopaminergic terminals, it
thus has to be considered that they are not equivalent
and potential different regulatory compensation of one
(or both) of these binding sites needs to be considered.
There is clear evidence that the DAT binding site can be
regulated by dopaminergic drugs (Vander Borght et al.,
1995; Wilson et al., 1996a); whether the DAT is regu-
lated after a neurotoxic insult, as part of a compensa-
tory mechanism of the remaining dopaminergic termi-
nals, is presently not fully established. In contrast, the
VMAT2 site may be more robust and not readily
regulated (Vander Borght et al., 1995), and a number of
investigators have utilized VMAT2 radioligand binding
as in vitro and in vivo measure of dopaminergic termi-
nal density in the rodent and human brain (Frey et al.,
1996; Scherman et al., 1989; Wilson et al., 1996a–c).
The early loss of the DAT site, with retention of the
VMAT2, would be consistent with rapid biochemical
changes of the dopaminergic terminal in response to
the neurotoxic insult, but without actual degeneration
of the terminal structure. A previous study of the
biochemical and morphological changes following MPTP
administration described a degenerative process begin-
ning as early as 12 hours after MPTP administration
but continuing for up to 4 days (Jackson-Lewis et al.,
1995). At some point, however, between 1 and three
days the terminals have suffered sufficient damage and
show losses of the vesicular structures, with concom-
mitant loss of the VMAT2 binding site, as demonstrated
in this study. This time sequence is very similar to the
results recently reported following methamphetamine
administration to mice, where losses (-77%) of DAT
radioligand binding ([3H]WIN 35,428 determined in
vitro) in the striatum were observed as early as one day
after neurotoxin injection, but significant losses of in
vitro [3H]dihydrotetrabenazine binding to the VMAT2
were not seen until 3 days later (Hogan and Sonsalla,
1998) and these losses of both transporters persist at
later time points (Frey et al., 1997; Hogan and Sonsalla,
1998).
The greater loss of in vivo VMAT2 radioligand bind-
ing, as compared to DAT radioligand binding, was not
expected. Other studies have noted a dissociation be-
tween various dopaminergic markers (DAT, TH, DA
concentrations) after MPTP lesioning of dopaminergic
nerve terminals of mouse brain (Donnan et al., 1987).
However, due to the wide variation in experimental
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design (discussed above), comparison of our results
with these earlier findings is impossible. In human
autopsy samples from both patients with Parkinson’s
disease as well as methamphetamine users, differential
losses of DAT and VMAT2 radioligand binding have
also been observed (Wilson 1996a–c); in those cases,
greater losses of DAT than VMAT2 radioligand binding
have been reported, which may perhaps reflects long-
term compensatory mechanisms involving the DAT.
Regional specificity of changes
The MPTP-induced losses of in vivo radioligand
binding to both the DAT and the VMAT2 were observed
only in the striatum. No significant losses of [11C]dihy-
drotetrabenazine binding were observed in the hypo-
thalamus, a region with clearly an intermediate concen-
tration of VMAT2 binding sites. Finally, no significant
MPTP-induced changes were observed in the cerebel-
lum for either radioligand, an important observation as
that region was chosen as the denominator for estima-
tions of specific binding.
Recovery of in vivo radioligand binding
There have been reports of recovery of dopaminergic
markers after MPTP administration, presumably by
sprouting of terminals (Donnan et al., 1987; Mitsumoto
et al., 1998; Ricuarte et al., 1987; Saitoh et al., 1987); in
some cases these changes have been seen as early as
the first 2 weeks after MPTP administration. In this
study, we did not observe any significant improvement
of in vivo DAT or VMAT2 radioligand binding during
the first 2-week period after a single high-dose MPTP
administration (Fig. 1).
Dual in vivo radiotracer studies: applications
The simultaneous, dual radiotracer in vivo technique
described here can be used to follow differential losses
of both the dopamine transporter (DAT) and the vesicu-
lar monoamine transporter type 2 (VMAT2) binding
sites following MPTP administrations. A single high
MPTP dose (55 mg/kg i.p.) produced significant losses
(.50%) of both [3H]methylphenidate (DAT) and [11C]di-
hydrotetrabenazine (VMAT2) binding to the mouse
striatum in vivo; losses of radioligand binding only to
the DAT occurred at one day after MPTP administra-
tion, whereas greater losses of VMAT2 radioligand
binding were observed at 3 and 14 days. This dual
radiotracer in vivo technique will next be applied to (1)
studies of differential long-term recovery of these trans-
porters after MPTP treatment and (2) evaluation of
which type of radioligand (DAT or VMAT2) provides
better measures of prevention or amelioration of degen-
erative effects of such neurotoxin treatments.
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